Hormone treatments in congestive heart failure

The Journal of International Medical Research
Lei Lei, Yuanjie Mao

Abstract

The common ultimate pathological feature for all cardiovascular diseases, congestive heart failure (CHF), is now considered as one of the main public health burdens that is associated with grave implications. Neurohormonal systems play a critical role in cardiovascular homeostasis, pathophysiology, and cardiovascular diseases. Hormone treatments such as the newly invented dual-acting drug valsartan/sacubitril are promising candidates for CHF, in addition to the conventional medications encompassing beta receptor blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and mineralocorticoid receptor antagonists. Clinical trials also indicate that in CHF patients with low insulin-like growth factor-1 or low thyroid hormone levels, supplemental treatment with growth hormone or thyroid hormone seems to be cardioprotective; and in CHF patients with volume overload the vasopressin antagonists can relieve the symptoms superior to loop diuretics. Furthermore, a combination of selective glucocorticoid receptor agonist and mineralocorticoid receptor antagonist may be used in patients with diuretic resistance. Finally, the potential cardiovascular efficacy and safety of incretin-based therapies, testosterone or e...Continue Reading

References

May 1, 1991·Hypertension·P DelafontaineR W Alexander
Jan 1, 1989·The Journal of Endocrinology·J IsgaardO G Isaksson
Jul 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·H P GulerE R Froesch
Feb 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·A J D'ErcoleL E Underwood
Oct 1, 1994·Endocrine Reviews·L SaccàS Fazio
Mar 28, 1996·The New England Journal of Medicine·S FazioL Saccà
Jun 1, 1997·European Journal of Clinical Investigation·J IsgaardB A Bengtsson
Jan 1, 1997·Biology of the Neonate·N S La MearT F Myers
Dec 19, 1998·European Heart Journal·J IsgaardB A Bengtsson
Jul 29, 1999·Journal of Molecular and Cellular Cardiology·R M WhitehurstM Li
Oct 3, 2000·Thyroid : Official Journal of the American Thyroid Association·G J Kahaly
Feb 15, 2001·The New England Journal of Medicine·I Klein, K Ojamaa
Apr 11, 2001·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·N NagayaK Kangawa
Jan 5, 2002·Journal of the American College of Cardiology·Raffaele NapoliLuigi Saccà
Jan 5, 2002·Journal of Cardiac Surgery·A PerrotK J Osterziel
Jul 2, 2002·JAMA : the Journal of the American Medical Association·Deborah GradyUNKNOWN HERS Research Group
Jul 19, 2002·JAMA : the Journal of the American Medical Association·Jacques E RossouwUNKNOWN Writing Group for the Women's Health Initiative Investigators
Apr 26, 2003·European Heart Journal·Peter J PughKevin S Channer
May 29, 2003·JAMA : the Journal of the American Medical Association·James B YoungUNKNOWN Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE ICD) Trial Investigators
Jul 10, 2003·American Heart Journal·Craig R LeeKirkwood F Adams
Mar 17, 2004·Heart·P J PughK S Channer
Apr 29, 2004·JAMA : the Journal of the American Medical Association·Mihai GheorghiadeUNKNOWN Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators
Jul 9, 2004·The Journal of Clinical Endocrinology and Metabolism·Misa ImaizumiKatsumi Eguchi
Sep 9, 2004·American Journal of Physiology. Endocrinology and Metabolism·Thomas NyströmAke Sjöholm
Nov 17, 2004·Annals of Internal Medicine·Li WeiBrian R Walker

❮ Previous
Next ❯

Citations

Jan 27, 2019·American Journal of Physiology. Heart and Circulatory Physiology·Pavel ZhabyeyevGavin Y Oudit
Jan 13, 2021·International Journal of Molecular Sciences·Jaqueline S da SilvaGisele Zapata-Sudo
Nov 24, 2021·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Cláudia FerreiraRita Nogueira-Ferreira

❮ Previous
Next ❯

Methods Mentioned

BETA
hormone replacement treatment

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.